Vanda Pharmaceuticals Inc. 8-K

What Happened
Vanda Pharmaceuticals Inc. announced results of operations and financial condition for the quarter and full year ended December 31, 2025 via a press release and an earnings conference call on February 11, 2026 (Item 2.02). The press release (furnished as Exhibit 99.1 to the 8‑K) includes Non‑GAAP financial measures. The company cautioned that statements made during the call include forward‑looking statements and referred investors to its SEC filings (10‑K, subsequent 10‑Q’s and 8‑K’s) for risks and assumptions.

Key Details

• Filing date: February 11, 2026 (Current Report on Form 8‑K).
• Reporting period: quarter and full year ended December 31, 2025.
• Exhibit: Press release dated February 11, 2026 furnished as Exhibit 99.1; press release discloses use of Non‑GAAP measures.
• Forward‑looking statements: Company warned that forward‑looking remarks on the call are subject to risks and will not be updated except as required by law.

Why It Matters
This filing signals that Vanda has released its Q4 and full‑year 2025 results and provided investor commentary via an earnings call — the press release and call are where you’ll find revenue, profit/loss, guidance and management commentary. Because the release uses Non‑GAAP measures and contains forward‑looking statements, investors should review the full press release and the company’s recent SEC filings (10‑K/10‑Q) to compare GAAP vs Non‑GAAP figures and to understand the listed risks and assumptions before making investment decisions.